Cero Therapeutics Holdings, Inc. (CERO) Stock Price & Analysis

Cero Therapeutics Holdings, Inc. (CERO) rose 0.00% to USD 0.01 as of September 8, 2026 at 05:50 UTC, according to Nexqual real-time market data.

CERO last closed at USD 0.01; the session ranged USD 0.01–0.01 on volume of 567,345 shares. Market capitalization is —, with a 52-week range of USD 0.01–5.72 (OQB). Source: Nexqual, September 8, 2026 at 05:50 UTC.

Key Statistics (as of September 8, 2026 at 05:50 UTC)

Technical Analysis (CERO)

Nexqual's technical model rates CERO "SELL" based on 2 bullish and 4 bearish signals across 128 daily candles, as of September 8, 2026 at 05:50 UTC.

From Cero Therapeutics Holdings, Inc.'s Latest SEC 10-K Filing (filed 2026-04-15)

Key Strengths & Strategy (as disclosed to the SEC)

• Our proprietary approach to T cell engineering, which enables us to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy.
• Unlike currently approved chimeric antigen receptor ("CAR-T") therapies which have largely been active in hematological B cell malignancies, we believe CER-1236 will be active in both hematological malignancies and solid tumors.   On November 14, 2024, we received notice from the FDA that the Investigational New Drug Application ("IND") was cleared after being put on a brief clinical hold due to insufficient nonclinical data to adequately judge off target toxicity.
• Nevertheless, despite such limitations, sales of CAR-T cell therapies are anticipated to grow rapidly over the next several years and are expected to exceed $10 billion globally by 2030.   We believe that the preferential attributes engineered into our CER-T cell therapy enable us to overcome many of the limitations which hinder the wider application of CAR-T technology.
• Accordingly, we have developed CER-T cell manufacturing processes that closely resemble those used to produce existing engineered CAR-T cells.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 05:50 UTC. This page is informational and not investment advice.